7/26/2023 0 Comments John beck 4d pharma4D’s pioneering work to develop promising therapies across a number of disease areas from oncology to the gut-brain axis is clearly differentiated through its MicroRx platform and LBP product candidates,” said John Beck, Chief Financial Officer of 4D pharma. “I look forward to contributing the success of 4D pharma at this exciting stage in its development. This includes three previous positions as Chief Financial Officer of publicly traded life sciences companies where he has achieved considerable results in areas including finance, business and corporate development, strategy, and commercialization. John Beck brings over 30 years of experience in financial and biopharmaceutical industry management experience. His deep experience and financial expertise as a CFO of several publicly traded life sciences companies will be critical as we further grow our company and global footprint,” said Duncan Peyton, Chief Executive Officer of 4D pharma. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.
0 Comments
Leave a Reply. |